Evidence map›Paper›PMID 38601569›Full record

ArticleHeliyon2024

Side effects and cognitive benefits of buspirone: A systematic review and meta-analysis.

Yue Du, Qing Li, Yikai Dou, Min Wang, Yu Wang, Yushun Yan, Huanhuan Fan, Xiao Yang, Xiaohong Ma

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Observational
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yue DuMental Health Center and Laboratory of Psychiatry, West China Hospital of Sichuan University, 610041, Chengdu, China.
Qing LiMental Health Center and Laboratory of Psychiatry, West China Hospital of Sichuan University, 610041, Chengdu, China.
Yikai DouMental Health Center and Laboratory of Psychiatry, West China Hospital of Sichuan University, 610041, Chengdu, China.
Min WangMental Health Center and Laboratory of Psychiatry, West China Hospital of Sichuan University, 610041, Chengdu, China.
Yu WangMental Health Center and Laboratory of Psychiatry, West China Hospital of Sichuan University, 610041, Chengdu, China.
Yushun YanMental Health Center and Laboratory of Psychiatry, West China Hospital of Sichuan University, 610041, Chengdu, China.
Huanhuan FanMental Health Center and Laboratory of Psychiatry, West China Hospital of Sichuan University, 610041, Chengdu, China.
Xiao YangMental Health Center and Laboratory of Psychiatry, West China Hospital of Sichuan University, 610041, Chengdu, China.
Xiaohong MaMental Health Center and Laboratory of Psychiatry, West China Hospital of Sichuan University, 610041, Chengdu, China.
Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Buspirone, a 5-hydroxytryptamine 1A (5-HT1A) receptor agonist, has been investigated for its use in various diseases. However, knowledge about its side effects and potential cognitive benefits in different conditions is limited. Cognitive impairment is also a prevalent symptom in many diseases, yet effective treatments are still lacking. Therefore, to explore the potential side effects of buspirone and the possible cognitive benefits of buspirone, we conducted a comprehensive search of several databases, including PubMed, Embase, Web of Science, Cochrane Review, Cochrane Trial, and ClinicalTrials.gov, to identify eligible randomized clinical trials. Our primary outcome measures included both side effects (adverse events) and cognitive benefits. For continuous variables, we utilized effect size with a 95% confidence interval (CI), whereas for dichotomous variables, we used odds ratios (OR) with a 95% CI. In total, 16 studies were included in this analysis, with 13 studies reporting on buspirone's side effects and 4 studies focusing on cognitive tasks. In terms of side effects, buspirone exhibited a higher rate of dizziness (OR = 4.66, 95% CI: 2.07-10.47), constipation (OR = 4.11, 95% CI: 1.34-12.55), and gastric distress (OR = 1.97, 95% CI: 1.03-3.78) than the placebo group. Regarding cognitive functions, buspirone showed significant benefits (g = 0.20, 95% CI: 0.06-0.34) while the placebo did not. Subgroup analysis indicated superior performance in visual learning and memory (g = 0.49, 95% CI: 0.21-0.78), logical reasoning (g = 0.42, 95% CI: 0.14-0.71), and attention (g = 0.37, 95% CI: 0.13-0.61) when compared to placebo. Our findings indicated that participants in the buspirone group experienced side effects of dizziness, constipation, and gastric distress in different diseases. Despite these adverse events, however, buspirone demonstrated significant cognitive benefits, particularly in the domains of visual learning and memory, logical reasoning, and attention.

Indexed as

BuspironeCognitive benefitsSide effects

Identifiers

PMID38601569
PMCPMC11004816
OpenAlexW4393392010

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.